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Background: Changes in energy metabolism of the cells are common to many kinds of tumors and are considered
a hallmark of cancer. Gas chromatography followed by time-of-flight mass spectrometry (GC-TOFMS) is a well-suited
technique to investigate the small molecules in the central metabolic pathways. However, the metabolic changes
between invasive carcinoma and normal breast tissues were not investigated in a large cohort of breast cancer
samples so far.
Results: A cohort of 271 breast cancer and 98 normal tissue samples was investigated using GC-TOFMS-based
metabolomics. A total number of 468 metabolite peaks could be detected; out of these 368 (79%) were
significantly changed between cancer and normal tissues (p<0.05 in training and validation set). Furthermore, 13
tumor and 7 normal tissue markers were identified that separated cancer from normal tissues with a sensitivity and
a specificity of >80%. Two-metabolite classifiers, constructed as ratios of the tumor and normal tissues markers,
separated cancer from normal tissues with high sensitivity and specificity. Specifically, the cytidine-5-
monophosphate / pentadecanoic acid metabolic ratio was the most significant discriminator between cancer and
normal tissues and allowed detection of cancer with a sensitivity of 94.8% and a specificity of 93.9%.
Conclusions: For the first time, a comprehensive metabolic map of breast cancer was constructed by GC-TOF
analysis of a large cohort of breast cancer and normal tissues. Furthermore, our results demonstrate that
spectrometry-based approaches have the potential to contribute to the analysis of biopsies or clinical tissue
samples complementary to histopathology.
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In a recent update, Hanahan and Weinberg added repro-
gramming of energy metabolism to the list of hallmarks
of cancer [1]. Historically, cancer was regarded as meta-
bolic disease long before being decoded as disease of
genes and mutations. More than 80 years ago, Otto War-
burg reported an increased anaerobic glycolysis in cancer
cells compared to normal cells [2]. Additional to the* Correspondence: jan.budczies@charite.de
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reproduction in any medium, provided the orWarburg effect [3,4], cancer cells exhibit increased pro-
tein and nucleotide synthesis [5,6], increased fatty acid
synthesis and changes in fatty acid metabolism [7-9]. Inte-
grating data of different sources, models of the altered
metabolism in cancer were developed, see for example
[4,10,11]. In recent years, there has been a renewed inter-
est in the altered metabolism of cancer cells coupled with
progress in development of new metabolic drugs [12]. In
order to obtain a comprehensive view on the metabolic
changes between invasive carcinomas and normal breast
tissues, herein a metabolomics study of breast cancer was
carried out with a focus on the low molecular weight
molecules of central metabolism. In a separate project, aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Principal components analysis (PCA) of the GC-TOFMS
data. The rotation matrix that connects the 162 identified
metabolites with the principal components (PCs) was determined
using the TS data. In the TS, the 1st PC captured 34.9% of the total
variance; in the VS the 1st PC captured 34.6% of the total variance.
The 1st PC was significantly decreased in cancer compared to
normal tissues in TS (p = 2.2E-22) and VS (p = 8.4E-41).
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a focus on altered membrane lipid metabolism [13].
Analytical chemistry methods allow the investigation
of the metabolic changes that occur in cancer tissues.
Using gas chromatography (GC), liquid chromatog-
raphy (LC) or capillary electrophoresis (CE) coupled
with mass spectrometry (MS) hundreds of molecules in
a tissue sample can be analyzed simultaneously. In two
preceding studies using gas chromatography followed
by time-of-flight mass spectrometry (GC-TOFMS) we
successfully profiled ovarian and colon cancer [14,15].
This approach, allowed the monitoring of hundreds of
small molecules with masses of up to 500 Da. Using
spectral libraries like BinBase [16] many of these me-
tabolite peaks can be mapped to metabolites with
known chemical structures and functions.
Breast cancer is a public health issue of global rele-
vance with more than one million new cases diagnosed
annually and more than 400,000 death cases worldwide
[17]. After surgery, adjuvant chemotherapy is offered to
most breast cancer patients to reduce the risk of relapse.
However, about 40% of the early breast cancer patients
have a low risk of developing distant metastases and of
dying because of the disease [18]. On the other hand,
aggressive subtypes like triple-negative breast cancer
have a poor prognosis and are difficult to treat [19].
New targeted therapies including small molecule inhibi-
tors and therapeutic antibodies are currently under de-
velopment and being tested in clinical trials [20],
however many of the new approaches achieved only
limited response rates. Therefore, as a step to persona-
lized medicine, a better understanding of the functional
pathway alterations in breast cancer is needed to avoid
over-treatment and select patients for individualized
and targeted therapies.
GC-TOFMS based metabolomics provides a wide
coverage of the central part of the cellular metabolism
including glycolysis, citrate cycle, amino acid and nu-
cleotide metabolism. These pathways are altered in can-
cer cells and can be targeted by metabolic drugs. Herein,
we report on the comparison of 275 invasive breast
cancer samples with 94 normal tissue samples using
GC-TOFMS. The purpose of this study is two-fold: (i)
to analyze the metabolic changes in the central path-
ways between invasive carcinoma and normal breast
tissues on a global scale and (ii) to identify key meta-
bolic markers that separate cancer from normal tissues
with high sensitivity and specificity.
Results
Metabolomics analysis of breast cancer
The entire cohort of breast cancer and normal tissues
was divided into a training set (TS, 226 samples, of
which 184 were tumor samples) and a validation set (VS,143 samples, of which 87 were tumor samples). Analysis
of the GC-TOFMS spectra of the TS samples led to the
detection of 468 most abundant metabolite peaks that
were present in breast cancer tissues. Subsequently,
these metabolites were measured in the VS. 162 of the
detected metabolite peaks could confidently be mapped
to known chemical structures and metabolite names.
Using unsupervised analysis methods we investigated
the contribution of the malignancy of the tissues to the
total variance of the dataset. The results of a principal
components analysis (PCA) of TS and VS are shown in
Figure 1. In the TS, the first two PCs captured 34.9%
and 5.2% of the total variance of the metabolomics data.
In the TS, the 1st PC was significantly decreased in can-
cer compared to normal tissues (p = 2.2E-22). In the VS,
the first two PCs captured 34.6% and 3.5% of the total
variance. Further, the 1st PC could be validated as being
decreased in cancer compared to normal tissues
(p = 8.4E-41). In summary, in TS and VS, the 1st PC cap-
tured more than one-third of the total variance of the
metabolomics data and correlated strongly with the ma-
lignancy of the studied tissue samples.
Metabolic changes between breast cancer and normal
tissue
Metabolite-by-metabolite analysis of the training set
(TS) led to detection of 427 significantly changed meta-
bolites between cancer (T) and normal tissues (N). Out
of these, 363 (85%) remained significant after Bonferroni
Figure 2 PROFILE clustering of 129 KEGG metabolites with fold changes between cancer and normal tissues. Ordering of the metabolites
along the x-axis reflects the distance of metabolites in the network of enzymatic reactions. Significant metabolite changes in the TS that could be
validated in the VS (green) and not significant or not validated metabolite changes (yellow).
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lysis of the validation set (VS). Among the validated
metabolites, 247 were decreased and 121 increased in
tumors, corresponding to 53% and 26% of the entire set
of metabolites detected by GC-TOFMS.
For functional analysis, PROFILE clustering [14] was
used to order the metabolites according to their mutual
proximity in the metabolic network. Figure 2 shows the
fold changes of 129 metabolites that are present in the
KEGG data base. By proceeding through the cluster map
form left to right, the metabolic changes include up-
regulation of many amino acids, changes in TCA cycle,
changes in glycerophospholipid metabolism, down-
regulation of the benzoic acid family, up-regulation of
most of the nucleotides and their phosphates, down-
regulation of the sugar cluster including sucrose, fruc-
tose and glucose, and down-regulation of most of the
free fatty acids.A metabolic network was constructed using Cytoscape
with MetScape plug-in (Figure 3). Two metabolites were
connected by an edge, if they can be converted into each
other by an enzymatic reaction. In breast cancer tissues,
glucose and other sugars were decreased while inter-
mediates of the glycolysis pathway such as glucose-6-
phosphate and 3-phospho-glycerate were increased. The
equilibrium between pyruvate and lactate was shifted to-
wards lactate. Many compounds of the TCA cycle were
increased, with the exception of alpha-keto-glutarate that
was decreased in cancer tissues.
Strong deregulation occurred in glutamate metabolism
with a shift of equilibrium from alpha-ketoglutarate (fold
change= -2.1, p = 2.4E-17) towards glutamate (fold
change= 6.5, p = 1.6e-40). Nineteen proteinogenic amino
acids (all except histidine) could be detected by the GC-
TOFMS approach. Out of these 16 were strongly
increased in the cancer tissues (all fold changes >1.9, all
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genic amino acids, asparagine, was decreased between
cancer a normal tissues (fold change= -1.6, p = 1.5e-07),
while glutamine and arginine remained unchanged.
Amphiphilic phospholipids are the building blocks of
the cell membrane and are synthesized from choline and
ethanolamine via the Kennedy pathway. Within this
pathway, we have detected a shift of the equilibrium from
ethanolamine (fold change = -2.0, p = 0.00041) to phos-
phoethanolamine (fold change= 16.3, p = 1.8e-44).
Nucleotides, nucleosides and their phosphates were gener-
ally increased in the cancer tissues with the strongest reg-
ulations belonging to CMP (fold change= 10.3, p = 1.4e-
57) and AMP (fold change= 7.8, p = 3.4e-49).
Metabolite based separation of cancer and normal tissues
In order to develop a metabolite-based molecular ap-
proach for the detection of breast cancer, we analyzedFigure 3 Metabolic map of breast cancer showing alterations in ener
and other pathways. Networks were generated using Cytoscape with the
compared to normal tissue (red nodes), significantly decreased metabolites
metabolites not in the GC-TOFMS screen (white nodes). The size of the noeach metabolite for its classifying power. 50 metabo-
lites, of which 20 have a known chemical structure,
separated tumor (T) from normal breast tissues (NB)
as well as tumor from normal adipose-rich tissues
(NA) with sensitivity and specificity >80%. The fold
changes of these marker metabolites are shown in
Figure 4. We found 13 tumor markers (increased in
T) and 7 normal tissue markers (increased in NB and
NA).
In order to enhance the separation, each of the tumors
markers was divided by each of the normal tissues mar-
kers yielding 13× 7=91 metabolite ratios that served as
classifiers. For each classifier, we defined a cut-off value
for the classification in cancer and normal tissues by
maximizing the sum of sensitivity and specificity. Then,
we applied a voting system counting each of the classifiers
above the cut-off +1, and each of the classifier below the
cut-off -1. The votes for 91 classifiers were summed andgy metabolism, catabolism of amino acids, nucleotide metabolism
Metscape plug-in. Significantly increased metabolites in tumor
(green nodes), unchanged metabolites (yellow nodes) and
des is proportional to the absolute value of the fold change.
Figure 4 Fold changes of 13 tumor markers and 7 normal
tissue markers. Each marker separates tumor (T) from normal
breast (NB) and from adipose-rich normal tissues (NA) with
sensitivity and specificity >80%.
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was observed between the votes for different classifiers:
For 217 tissue samples (58.8%) there was unisonous agree-
ment among all classifiers, for 319 tissue samples (86.4%)
more than 90% of the classifiers agreed on malignancy
status.
Next, we compared the classification result obtained
by the majority of the classifiers with the histopatho-
logical classification that is the gold standard for cancer
detection. Only 8 out of 271 tumors and 6 out of 98 nor-
mal tissues were classified incorrectly, leading to a sensi-
tivity of 97.0% and a specificity of 93.9% of the
molecular test. Further, restricting the analysis to the
319 tissues where more than 90% of the classifiers
agreed, only one tumor and four normal tissues were
classified incorrectly, leading to a sensitivity of 99.6%
and a specificity of 95.5%.
Among all classifiers the ratio of cytidine-5-
monophosphate / pentadecanoic acid had the highest
significance for changing between cancer and normal
tissues (T vs. N: p = 8.3E-74) and at the same time had
the highest significance for changing between malignant
and normal breast tissues (T vs. NB: p = 7.8E-14). Maxi-
mizing the sum of sensitivity and specificity lead to a
cut-off value = 0.39. Using this cut-off point, only 14 out
of 271 tumors and 6 out of 98 normal tissues were in-
correctly classified leading to 94.8% sensitivity and 93.9%
specificity. Histogram and ROC curve of the classifier
are shown in Figure 6.
Nearest centroid classification
We investigated the performance of classifiers including
2, 3, . . ., 162 metabolites with known structure for the
separation of cancer from normal tissues. To estimate
sensitivity and specificity of the classifiers, we combined
nearest centroid classification with a multiple random
validation strategy, as in [21]. It turned out that on aver-
age a sensitivity of about 96% and a specificity of about
94% was obtained independent of the number of meta-
bolites. The classification results did not improve when
a larger number of metabolites was used for classifica-
tion (Table 1 and data not shown).
Discussion
Our results show that tissues collected during breast
surgery have reproducible metabolite profiles that can be
analyzed by using GC-TOFMS. Using this approach, 478
metabolite peaks could be detected and quantified; 79%
of these were changed between cancer and normal tis-
sues. Thus, there is a difference in the concentrations of
many metabolites between cancer and normal tissues in-
cluding changes as high as tenfold and more for some
metabolites. The high rate of validated metabolites in a
predefined training-validation analysis, even after theconservative Bonferroni correction, shows that the GC-
TOFMS is a robust approach to detect the metabolite
changes associated with malignant progression. Data ac-
quisition at different time points is considered as a main
source of variance in many GC-MS studies. However,
the high degree of reproducibility (86% of metabolic
changes) between training and test data set underscores
the robustness GC-TOFMS platform and of the detected
metabolic changes in the current study.
A metabolic map of breast cancer was constructed by
visualizing the metabolite changes in the metabolic net-
work including pathways like glycolysis, TCA cycle, nu-
cleotide metabolism and catabolism of amino acids. The
metabolic map can serve as a tool for hypothesis build-
ing about the metabolic processes in breast cancer and
help to develop strategies for the therapeutic targeting of
metabolism in cancer cells. Several metabolic drugs,
some of them targeting the central energy metabolism,
are currently under development and investigated in
clinical studies [12].
Cancer is commonly considered as a genetic disease
that is driven by mutations of oncogenes and tumor sup-
pressor genes. However, one of the major underlying
purposes of those genetic and gene expression changes
is to create a metabolic phenotype for cancer cells that is
essential for tumor cell growth and survival [8,22]. The
metabolic phenotype of cancer includes alterations in
glycolysis, amino acid metabolism, nucleotide metabol-
ism and glycerophospholipid metabolism that were con-
firmed in the current study.
Figure 5 Metabolite based prediction of the malignancy of 369 tissues. 91 classifiers are constructed from the 20 most discriminatory
metabolites that are shown in Figure 4. The bars show the results of an equal voting of the 91 classifiers. A majority decision predicts the
malignancy with high accuracy (sensitivity = 97.0%, specificity = 93.9%).
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plasma, can be metabolized to pyruvate and lactate
through glutamate, alpha-keto-glutarate and via the cit-
ric acid cycle. This process, termed glutaminolysis is an
important source of energy, carbon and nitrogen in can-
cer cells [23]. In the present study, we have observed
strong regulation of this pathway including a strong up-Figure 6 Prediction of tissue malignancy by the ratio R = cytidine-5-m
5-monophosphate in cancer compared to normal tissues. (B) Down-regula
Histogram showing the distribution of the ratio R in cancer and normal tiss
normal tissues (p = 8.3e-74, Welch’s t-test). A cut-off at R = 0.39 maximizes
confidence intervals for sensitivity (red lines) and specificity (green lines). Th
the separation of cancer from normal tissues.regulation of glutamate (fold change = 6.5) while glutam-
ine was unchanged. This suggests that glutamine
metabolism and in particular glutaminase, the enzyme
that converts glutamine to glutamate, should be a poten-
tial target for intervention. In the 1980s three glutamine
analogs raised great expectations as possible antineoplas-
tic agents. But the promising results obtained in modelonophosphate / pentadecanoic acid. (A) Up-regulation of cytidine-
tion of pentadecanoic acid in cancer compared to normal tissues. (C)
ues (x-axis: log2 scale). R was significantly higher in cancer than in
the sum of sensitivity and specificity. (D) ROC curve of R with
e cut-off leads to at sensitivity of 94.8% and a specificity of 93.9% for
Table 1 Prediction of tissue malignancy by metabolite ratios and by nearest centroid classification
method # of metabolites sensitivity specificity
metabolite ratios: CMP / pentadecanoic acid 2 94.8% 93.9%
metabolite ratios: majority vote of 91 classifiers 20 97.0% 93.9%
cancerclass: nearest centroid 2 95.1% (86.4% - 97.6%) 93.9% (81.8% - 100%)
cancerclass: nearest centroid 20 97.1% (94.2% - 99.1%) 93.9% (84.8% - 100%)
cancerclass: nearest centroid 162 95.1% (93.2% - 97.1%) 93.9% (84.8% - 100%)
CMP : cytidine-5-monophosphate.
The metabolite ratio method was developed in the current work. Nearest centroid classification was executed using the R package cancerclass [37]. For the latter
method, classification rates including 95% confidence intervals were estimated using multiple random validation.
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dose limiting side effects and ineffectiveness of treat-
ment [24]. However, recently a small molecule inhibitor
was shown to target GLS (kidney-type glutaminase) and
to have antiproliferative activity in breast cancer cells
while being unharmful to normal cells [25]. Further-
more, a connection between MYC (v-myc myelocytoma-
tosis viral oncogene homolog), a master transcription
factor and oncogene that is deregulated in many cancers
and glutamine metabolism has been described [11].
MYC is known to be amplified in about 5% of breast
cancers and associated with a more aggressive subtype
and shortened survival [26].
In the GC-TOFMS metabolomics based approach we
observed a two- to four-fold down-regulation of almost
all detected free fatty acids (Figure 2). The down-
regulation of fatty acids seems to contradict the up-
regulation of fatty acid synthase (FASN) and increased
de novo fatty acid synthesis that is found in many can-
cers [5,9]. Interestingly, a lipidomics study of breast can-
cer showed an up-regulation of many membrane lipids
in cancer compared to normal tissues [13]. Thus, the
metabolomics described in this paper together with the
previously reported lipidomics data support the hypoth-
esis that de novo fatty acid synthesis is potentially
increased in breast cancer, but free fatty acids are rapidly
metabolized to synthesize membrane phospholipids.
The GC-TOFMS data also showed a shift of the equi-
librium from ethanolamine that was decreased to
phospho-ethanolamine that was highly increased in
the cancer tissues possibly indicating a stimulation of
the Kennedy pathway. To correlate these changes with
the content of membrane lipids, we have extracted the
total content of different kinds of membrane lipids from
the UPLC-MS data published before [13]. However,
there were neither pronounced correlations between
phospho-ethanolamine and the total content of
phosphatidylethanolamine (PE) nor between phospho-
ethanolamine and the total content of phosphatidylcho-
line (PC), see Figure 7A. The mechanism behind might
be that, in tumors tissues, the Kennedy pathway isregulated in such a way, that a sufficient concentration
of phospho-ethanolamine is always available. In fact, the
same choline kinases that catalyse the reaction of cho-
line to phospho-choline also catalyse the reaction of
ethanolamine to phospho-ethanolamine. Choline kinases
were detected to be up-regulated in tumors and repre-
sent potential targets for therapeutic intervention [27].
In order to develop a classifier that separates between
cancer and normal tissues, we identified 13 increased
metabolites and 7 decreased metabolites that separated
cancer from normal tissues with sensitivity and specifi-
city >80%. We did not detect any perfect biomarker in
the sense that a single metabolite was abundant and
specific to cancer tissue, but absent in normal tissues
or vice versa. Therefore, we built ratios of metabolites
in order to construct scale-invariant tissue classifiers
that are independent of the amount of tissue under in-
vestigation and do not depend on data normalization.
These two-metabolite classifiers separated cancer from
normal tissues with high sensitivity and specificity and
had a high agreement among each other. In an exten-
sive additional analysis we investigated the performance
of classifiers that include a larger number of metabo-
lites using a multiple random validation strategy. It
turned out that classifiers including more metabolites
did not outperform classifiers including only two meta-
bolites (Table 1). This result underscores the relevance
of the two-metabolite ratio classifiers as a promising
strategy for diagnostic classification.
The metabolite ratio cytidine-5-monophosphate/
pentadecanoic acid showed the strongest discrimination
between cancer and normal tissues and permitted de-
tection of cancer with a sensitivity of 94.8% and a spe-
cificity of 93.9%. Pentadecanoic acid (C15:0) is a known
fatty acid present in milk and it has been found to be a
good marker of milk fat intake when found in serum.
However, a heatmap of the free fatty acids shows a high
correlation of the free fatty acids C14:0, C15:0, C16:0,
C17:0, C18:0, C20:0 in the METAcancer cohort (see
Figure 7B, all Pearson correlations >0.82). Thus, in the
classifier, it is possible to replace pentadecanoic acid by
Figure 7 Heatmaps of glycerophospholipids and free fatty acids. (A) Heatmap of ethanolamine and phospho-ethanolamine, both detected
by GC-TOFMS, and the total amounts of phosphatidylethanolamine (PE), phosphatidylcholines (PC), spingomylins (SM) and triglycerides (TG), all
detected by UPLC-MS. (B) Heatmap of 18 free fatty acids, all detected by GC-TOFMS. The fatty acids are annotated by the number of carbon
atoms, the number of double bonds and the omega position of the double bonds. The bars at the top of the heatmaps encode the type of
tissue: invasive carcinoma (T) = red, normal breast tissue (NB) = dark grey, adipose-rich normal tissue (NA) = light grey.
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cluding ligoneric acid (24:0) or heptadecanoic acid
(17:0) instead of pentadecanoic acid to a large extend
coincide with the classifiers that include pentadecanoic
acid.
For the detection of metabolite changes, we worked
with a predefined training set (TS) and validation set (VS).
All of the 20 most discriminatory metabolites are among
the validated changed metabolites between cancer (T) and
normal tissues (N). It should be noted, though, that nor-
mal breast tissue might consist of normal epithelium as
well as various amounts of adipose tissue. Therefore, it
was important to distinguish different kinds of normal tis-
sues (NA and NB) and to develop a classifier that is inde-
pendent of the fat content of the tissue. Thus, only
metabolites that separated cancer from both, normal
breast (NB) and normal adipose-rich tissues (NA) were
included in the final classifier. This part of the analysis
could only be performed in the pooled TS and VS due to
a low number of normal breast samples. Another limita-
tion of the current study is its retrospective character and
the use of preselected samples that were enriched for can-
cer or normal cells. The cancer classifiers developed here
need to be further validated using random samples from
biopsying or surgery. In doing so, concordance with histo-
pathology (accuracy) and reproducibility in repeated ana-
lyses of the same tissue (precision) of the classifiers should
be further evaluated.A critical factor determining whether a method is
applicable for routine cancer diagnostics, for example
during surgery, is the time needed for sample ana-
lysis. In order to cope with the inherent heterogeneity
nature of the tissues, it is necessary to probe various
areas of the tissue and still keep the total analysis
time in the range of minutes. There is recent progress
in automation and miniaturization of MS devices and
such tools are expected to become cheaper and easier
to handle during the next few years [28,29]. First
hand-portable, automated GC-MS devices is commer-
cially available today [30]. Additionally, an automated
LC/CE-MS device in the size of a personal computer
is being developed in the European ARROWS FP7
project [31]. Automation of sample acquisition, prep-
aration and data generation will be important to
translate MS based tissue investigations approaches
into clinical applications.
Conclusions
For the first time, a metabolic map of breast cancer was
constructed by GC-TOF analysis of a large cohort of
breast cancer and normal tissues. In future, MS based
devices could contribute to the analysis of biopsies and
surgical samples. While metabolite analyses will not re-
place microscopic evaluation, metabolomics could be
used complementary to histopathology, e.g. for an initial
quality control of biopsies directly after sampling or as
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Methods
Study cohort
The study cohort consisted of 369 fresh frozen breast
tissues that were collected at the Charité Hospital in the
tissue bank of the European FP7 METAcancer consor-
tium. The project was approved by the institutional re-
view board of the Charité Hospital (EA1/139/05). For
histopathological quality control, an H&E section of
each frozen tissue was evaluated by a pathologist. 271
samples contained cancer tissue and had a tumor area
≥40% (T), the remaining 98 samples contained exclu-
sively normal tissue (N). The normal tissues included 27
samples with ≥40% normal breast tissue (NB) and 71
adipose-rich samples with <40% normal breast tissue
(NA).
As a basis for a predefined training-validation strategy,
the entire cohort was divided in a training set (TS) of
184 + 42 (T+N) samples and a validation set (VS) of
87 + 56 samples. In detail, tumor samples were split ran-
domly in a way that training (2/3) and validation (1/3)
sets did not differ with respect to the following para-
meters: tumor stage, tumor grade, age (≤50 and
>50 years) and estrogen receptor status. To this end,
100,000 splits were randomly drawn and the one with
the lowest Kullback-Leibler divergence was chosen. All
42 normal tissues in the TS were paired with tumor tis-
sues in the TS from the same patients. The VS included
24 normal tissues that were paired with tumor tissues
and 32 additional unpaired normal tissues.
GC-TOFMS based metabolomics
GC-TOFMS data acquisition of the 369 tissues was per-
formed as previously published [16], following the guide-
lines of the metabolomics standard initiative [32]. Briefly,
20 mg frozen breast tissue samples were homogenized and
extracted with 1 ml degassed isopropanol/acetonitrile/water
(3/3/2) at 4°C for 5 min. The extracts were subsequently
dried down and re-suspended in 50% aqueous aceto-
nitrile to remove most of the complex lipids. After
dry evaporation, extracts were derivatized and sub-
jected to GC-TOFMS (Leco Pegasus IV) fitted with
automatic liner exchange-cold injection (Gerstel). Raw
data were deconvoluted using ChromaTOF (Leco) and
mass spectra were exported for further data proces-
sing by the BinBase database, including identification
of metabolites [16]. The TS and VS samples were
analyzed as separate cohorts at two different time
points (11/2008 and 1/2009). Data analysis was carried
out using the statistical computing and graphics environ-
ment R [33]. For data normalization, each sample was
divided by the sum over the measurements of themetabolites with known structure. Prior to analysis, data
were transformed by log-2 scaling.
Principal components analysis
Using unsupervised multivariate data analysis methods,
we investigated whether the malignancy of tissues was
among the main contributors to the variance of metabo-
lites. To this end, the measurements of each identified
metabolite were zero centered and principal components
analysis (PCA) was performed. The rotation matrix that
connects the 162 metabolites with the principal compo-
nents was determined from the TS data. By multiplica-
tion with the rotation matrix, the principal components
were calculated for the TS and VS. Finally, the principal
components were investigated for changes between can-
cer and normal tissue samples. The significance of
changes was assessed using Welch’s t-test.
Detection of metabolite changes
We performed a supervised analysis and investigated
each metabolite for change between cancer and normal
tissues. A metabolic change was termed as detected, if
there was a significant change in the TS (p< 0.05,
Welch’s t-test, two-sided). A metabolic change was
termed as validated, if there was a significant change in
the VS in the same direction (p< 0.05, Welch’s t-test,
one-sided). Using PROFILE clustering, the detected
metabolite changes were analyzed in the context of the
underlying metabolic pathways. PROFILE clustering is
a bioinformatic method that groups metabolites with
respect to the topologic distance within the metabolic
network [14]. The distances for clustering are calcu-
lated from the network of enzymatic reactions as it is
available from the KEGG database [34].
Network reconstruction and visualization
A metabolic network was generated using Cytoscape
[35] and MetScape, version 1.01 [36]. MetScape is a
plug-in for Cytoscape that integrates reaction and path-
way information from KEGG. The metabolites detected
by GC-TOFMS were imported as the root for the net-
work. MetScape automatically expanded the network
with a depth of 2 reactions around each of the metabo-
lites. Metabolites are mapped to nodes and reactions are
mapped to edges connecting the nodes. The resulting
network was manually curated by erasing nodes at the
periphery of the network and by removing reactions that
are not part of the human metabolism. Additional meta-
bolites were added where the expansion depth was not
sufficient. Information on the metabolic changes be-
tween breast cancer and normal tissues was imported as
node attributes. The direction of regulation was visua-
lized by the color of nodes and the fold change by the
size of nodes.
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Separation of tumors (T) from normal breast tissues (NB)
and tumors from adipose-rich tissues (NA) were investi-
gated using receiver operator characteristics (ROC) curves.
Metabolites that exceeded 80% sensitivity and specificity for
both comparisons were considered as classifying. Classify-
ing metabolites were divided in tumor markers (increased
in T) and normal tissues markers (increased in NB and
NA). Classifiers were constructed by the ratio of each pos-
sible combination of a tumor and a normal tissue marker.
The quality of each classifier was investigated in an ROC
analysis. For each classifier, an optimal cut-off point was
determined by maximizing the sum of sensitivity and speci-
ficity. A voting system was applied counting each of the
classifiers above the cut-off +1, and each of the classifier
below the cut-off -1. Finally, each of the tissues was pre-
dicted to belong to the class with the majority of votes.
Multiple random validation strategy
We investigated the performance of classifiers including
2, 3, . . ., 162 of the metabolites with known structure for
the separation of cancer from normal tissues. For each
of the metabolite numbers 200 random splits of the
GC-TOFMS data were drawn. All training data sets
included the same number of tumor and normal tissues
(65 of each tissue type). Classification was performed
by the nearest centroid method with respect to euclid-
ean distance after feature selection based on Welch’s
t-test. All analyses were conducted using the R pack-
age cancerclass that is available from the open source
project Bioconductor [37].Competing interests
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